Rhythm Pharmaceuticals Inc. [RYTM] stock prices are down -5.76% to $41.10 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RYTM shares have gain 0.51% over the last week, with a monthly amount glided 1.46%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, April 2024, Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing. In a post published today on Yahoo Finance, — Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 –.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc. [NASDAQ: RYTM] stock has seen the most recent analyst activity on December 19, 2023, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $55 from $29. Previously, BofA Securities upgraded its rating to Buy on August 01, 2023, and elevated its price target to $27. Goldman upgraded its rating to a Buy but stick to its price target of $28 on August 08, 2022. BofA Securities upgraded its rating to a Neutral and raised its price target to $20 on August 05, 2022. Needham reiterated a Buy rating for this stock on June 17, 2022, and downed its price target to $25.
The stock price of Rhythm Pharmaceuticals Inc. [RYTM] has been fluctuating between $15.50 and $52.57 over the past year. Currently, Wall Street analysts expect the stock to reach $28.33 within the next 12 months. Rhythm Pharmaceuticals Inc. [NASDAQ: RYTM] shares were valued at $41.10 at the most recent close of the market. An investor can expect a potential drop of -31.07% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
The Rhythm Pharmaceuticals Inc. [NASDAQ:RYTM] reported sales of 77.43M for trailing twelve months, representing a surge of 175.70%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.38%, Pretax Profit Margin comes in at -2.38%, and Net Profit Margin reading is -2.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.96 and Total Capital is -0.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.49 points at the first support level, and at 39.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.19, and for the 2nd resistance point, it is at 43.28.
Rhythm Pharmaceuticals Inc. [RYTM] reported earnings per share of -$0.7 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.7/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.76 per share as compared to estimates of -$0.74 per share, a difference of -$0.02 representing a surprise of -2.70%.
Ratios To Look Out For
It’s worth pointing out that Rhythm Pharmaceuticals Inc. [NASDAQ:RYTM]’s Current Ratio is 5.58. Also, the Quick Ratio is 5.43, while the Cash Ratio stands at 1.09. Considering the valuation of this stock, the price to sales ratio is 31.92, the price to book ratio is 14.39.
Transactions by insiders
Recent insider trading involved German Christopher Paul, Corporate Controller & CAO, that happened on Apr 02 ’24 when 368.0 shares were sold. Chief Technical Officer, Shulman Joseph completed a deal on Mar 21 ’24 to sell 18235.0 shares. Meanwhile, EVP, Head of North America Lee Jennifer Kayden sold 18235.0 shares on Mar 20 ’24.
